Double trouble
This article was originally published in The Tan Sheet
Executive Summary
Tishcon files second lawsuit against Twinlab, this time alleging latter's Twinsorb CoQ10 supplement infringes on patent covering "method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same," granted to Tishcon in May 2000. Complaint, filed July 11, seeks patent enforcement, unspecified damages. First suit, filed several days earlier, asserts Twinsorb ad claims are false, misleading, disparaging, seeks damages over $50 mil. (1"The Tan Sheet" July 23, p. 6). Twinlab apparently has yet to respond to the complaints
You may also be interested in...
Tishcon
Carni Q-Gel, a combination of Tishcon's hydrosoluble Q-Gel coenzyme Q10 and Sigma Tau's L-carnitine fumarate, launched Oct. 13. Delivery form of Q-Gel permits 100% bioavailability, Tishcon says. To "promote a healthy heart and vascular function," each softgel of Carni Q-Gel contains 30 mg coenzyme Q10; consumers are advised to take one to two soft gel, as needed three times a day with meals. Tishcon has filed two lawsuits against Twinlab alleging its Twinsorb CoQ10 supplement infringes on patents held by Tishcon (1"The Tan Sheet" Aug. 6, p. 20)
Tishcon $50 Mil. Lawsuit Alleges Twinsorb CoQ10 Claims False, Misleading
Twinlab's claims that its Twinsorb CoQ10 is "9 times more absorbable" than competing products are "false, misleading and disparaging," Tishcon Corp. asserts in a $50 mil. lawsuit filed in a New York federal court July 9.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC